<DOC>
	<DOC>NCT02386098</DOC>
	<brief_summary>The purpose of this study is to evaluate whether the combination of BMS-955176 with atazanavir (ATV) [with or without ritonavir (RTV)] and dolutegravir (DTG) is efficacious, safe, and well-tolerated in HIV-1 infected treatment experienced adults.</brief_summary>
	<brief_title>Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Men and nonpregnant women, at least 18 years of age Antiretroviral treatmentexperienced, defined as having documented evidence of having failed 1 or 2 regimens that include 2 or 3 classes of antiretroviral (ARV) (with or without documented resistance) CD4+ Tcell count &gt; 50 cells/mm3 Screening genotype/phenotype indicating susceptibility to study drugs (unboosted ATV, FC &lt; 2.2; DTG; TDF) Antiretroviral treatmentexperienced adults who have failed &gt; 2 ARV regimens Resistance or partial resistance to any study drug determined by tests at Screening Historical or documented genotypic and/or phenotypic drug resistance testing showing certain resistance mutations to ATV, TDF, RAL, Protease Inhibitors, and certain TAMs Chronic hepatitis B virus (HBV)/ hepatitis C virus (HCV) Blood tests that indicate normal liver function Hemoglobin &lt; 8.0 g/dL, Platelets &lt; 50,000 cells/mm3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>